Development of a mechanistic model to predict synthetic biotic activity in healthy volunteers and patients with phenylketonuria
Mark R. Charbonneau, William S. Denney, Nicholas G. Horvath and 4 more
Communications Biology · 2021
doi:10.1038/s42003-021-02183-1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Mark Charbonneau et al. develop a mathematical model that describes the behavior of an engineered bacterial therapeutic, SYNB1618, in the human gastrointestinal tract and its effects on plasma phenylalanine (Phe) levels. This model enables the authors to predict plasma Phe lowering by SYNB1618 in patients with phenylketonuria.
Abstract licence: CC BY-NC-ND
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.